Management of patients with type 2 diabetes and MASLD: An overview and joint statement

Type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD) are two highly prevalent diseases with rapidly growing incidences worldwide. They are frequently associated due to their shared pathophysiology and their bidirectional influence. MASLD-related liver fibrosis is a major driver of hepatic complications and is associated with increased risk of extrahepatic complications, such as cardiovascular and renal diseases in patients with T2D. In this setting, systematic screening for advanced fibrosis related to MASLD is now unanimously recommended for patients with T2D, due to its high prevalence and specific therapeutic management. The French Association for the Study of the Liver (AFEF) and the Francophone Diabetes Society (SFD) convened a group of experts to summarize the current knowledge on MASLD screening and therapeutic management in patients with T2D and thus provide a roadmap to healthcare professionals, especially diabetologists or primary care physicians. Our focus will be on the particularities of dietary and behavioral management, pharmacological treatment of T2D, and bariatric procedures in cases of MASLD. Our goal is to provide clinical guidance for adapting drug therapy in the presence of significant fibrosis in order to slow the progression of liver disease and reduce the risk of associated clinical events.

Authors

Institutions

Publication Details

Journal
Diabetes & Metabolism
Published
2025-10-15
DOI
https://doi.org/10.1016/j.diabet.2025.101709
Citations
2
Primary Topic
Diet and metabolism studies
Type
article
Field-Weighted Citation Impact
2.33
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Management of patients with type 2 diabetes and MASLD: An overview and joint statement

Raluca Pais, Bertrand Cariou, Sarra Smati, Laurent Castéra et al.
2 citations
Diabetes & Metabolism
Diet and metabolism studies
2.33
article

Management of patients with type 2 diabetes and MASLD: An overview and joint statement

Raluca Pais, Bertrand Cariou, Sarra Smati, Laurent Castéra, Maéva Guillaume, Yasmina Chouik, Cyrielle Caussy, Clémence M. Canivet, Alexia Rouland, Jean‐Baptiste Julla, Rodolphe Anty, Pierre Gourdy, Thomas Mouillot, Lawrence Serfaty, Blandine Tramunt, Bruno Guerci, Jérôme Boursier, Guillaume Lassailly, Claire Carette, Jean-Michel Petit, Armand Garioud, Lucia Parlati, Bruno Vergès
article en
2 citations

Abstract

Type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD) are two highly prevalent diseases with rapidly growing incidences worldwide. They are frequently associated due to their shared pathophysiology and their bidirectional influence. MASLD-related liver fibrosis is a major driver of hepatic complications and is associated with increased risk of extrahepatic complications, such as cardiovascular and renal diseases in patients with T2D. In this setting, systematic screening for advanced fibrosis related to MASLD is now unanimously recommended for patients with T2D, due to its high prevalence and specific therapeutic management. The French Association for the Study of the Liver (AFEF) and the Francophone Diabetes Society (SFD) convened a group of experts to summarize the current knowledge on MASLD screening and therapeutic management in patients with T2D and thus provide a roadmap to healthcare professionals, especially diabetologists or primary care physicians. Our focus will be on the particularities of dietary and behavioral management, pharmacological treatment of T2D, and bariatric procedures in cases of MASLD. Our goal is to provide clinical guidance for adapting drug therapy in the presence of significant fibrosis in order to slow the progression of liver disease and reduce the risk of associated clinical events.

Diabetes & MetabolismVol. 51(6)
Université Claude Bernard Lyon 1 (FR), Centre National de la Recherche Scientifique (FR), Inserm (FR), Université de Bourgogne (FR), Université Paris Cité (FR), Hôpital Beaujon (FR), Centre Hospitalier Universitaire de Lille (FR), Centre Hospitalier Universitaire de Nice (FR), Hôpital de la Croix-Rousse (FR), Hôpital Cochin (FR), Hôpital Beau-Séjour (CH), Assistance Publique – Hôpitaux de Paris (FR), Hospices Civils de Lyon (FR), Hôpital Européen Georges-Pompidou (FR), Hôpital Européen (FR), Centre Hospitalier Universitaire d'Angers (FR), Hôpital Lyon Sud (FR), Centre de Recherche en Nutrition Humaine Rhône-Alpes (FR), CHU Dijon Bourgogne (FR), Hôpital Lariboisière (FR), Clinique Pasteur (FR), Institut du Thorax (FR), Centre Hospitalier Intercommunal de Villeneuve-Saint-Georges (FR), Hôpitaux Universitaires de Strasbourg (FR), Institut des Maladies Métaboliques et Cardiovasculaires (FR), Fondation pour l’innovation en Cadiométabolisme et Nutrition (FR), Hôpital Civil, Strasbourg (FR), Institut National des Sciences Appliquées de Lyon (FR), Université de Lorraine (FR), Nantes Université (FR)
Openalex Percentile: Top 10%
Diet and metabolism studies
2.33
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.